Literature DB >> 21061197

Role of PD-1 in regulating T-cell immunity.

Hyun-Tak Jin1, Rafi Ahmed, Taku Okazaki.   

Abstract

Programmed cell death-1 (PD-1) is a member of the CD28 superfamily that delivers negative signals upon interaction with its two ligands, PD-L1 or PD-L2. PD-1 and its ligands are broadly expressed and exert a wider range of immunoregulatory roles in T cells activation and tolerance compared with other CD28 members. Subsequent studies show that PD-1-PD-L interaction regulates the induction and maintenance of peripheral tolerance and protect tissues from autoimmune attack. PD-1 and its ligands are also involved in attenuating infectious immunity and tumor immunity, and facilitating chronic infection and tumor progression. The biological significance of PD-1 and its ligand suggests the therapeutic potential of manipulation of PD-1 pathway against various human diseases. In this review, we summarize our current understanding of PD-1 and its ligands ranging from discovery to clinical significance.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21061197     DOI: 10.1007/82_2010_116

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  122 in total

1.  Enhancement of SIV-specific cell mediated immune responses by co-administration of soluble PD-1 and Tim-3 as molecular adjuvants in mice.

Authors:  Lijun Xiao; Dimin Wang; Caijun Sun; Pingchao Li; Yi Jin; Liqiang Feng; Ling Chen
Journal:  Hum Vaccin Immunother       Date:  2013-12-10       Impact factor: 3.452

2.  Immunodominant Dengue Virus-Specific CD8+ T Cell Responses Are Associated with a Memory PD-1+ Phenotype.

Authors:  Ruklanthi de Alwis; Derek J Bangs; Michael A Angelo; Cristhiam Cerpas; Anira Fernando; John Sidney; Bjoern Peters; Lionel Gresh; Angel Balmaseda; Aruna D de Silva; Eva Harris; Alessandro Sette; Daniela Weiskopf
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

3.  Dysregulation of the PD-1/PD-L1 pathway contributes to the pathogenesis of celiac disease.

Authors:  Candelaria Ponce de León; Miguel Angel López-Casado; Pedro Lorite; Teresa Palomeque; María Isabel Torres
Journal:  Cell Mol Immunol       Date:  2019-06-26       Impact factor: 11.530

4.  Merck Ad5/HIV induces broad innate immune activation that predicts CD8⁺ T-cell responses but is attenuated by preexisting Ad5 immunity.

Authors:  Daniel E Zak; Erica Andersen-Nissen; Eric R Peterson; Alicia Sato; M Kristina Hamilton; Joleen Borgerding; Akshay T Krishnamurty; Joanne T Chang; Devin J Adams; Tiffany R Hensley; Alexander I Salter; Cecilia A Morgan; Ann C Duerr; Stephen C De Rosa; Alan Aderem; M Juliana McElrath
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-14       Impact factor: 11.205

5.  Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced Malignancies.

Authors:  Tarek Taha; David Meiri; Samira Talhamy; Mira Wollner; Avivit Peer; Gil Bar-Sela
Journal:  Oncologist       Date:  2019-01-22

6.  Elevated tumor-associated antigen expression suppresses variant peptide vaccine responses.

Authors:  Charles B Kemmler; Eric T Clambey; Ross M Kedl; Jill E Slansky
Journal:  J Immunol       Date:  2011-09-21       Impact factor: 5.422

7.  DNA methylation of immune checkpoints in the peripheral blood of breast and colorectal cancer patients.

Authors:  Asma A Elashi; Varun Sasidharan Nair; Rowaida Z Taha; Hibah Shaath; Eyad Elkord
Journal:  Oncoimmunology       Date:  2018-11-10       Impact factor: 8.110

8.  Menopausal status influences the expression of programmed death (PD)-1 and its ligand PD-L1 on immune cells from the human female reproductive tract.

Authors:  Zheng Shen; Marta Rodriguez-Garcia; Mickey V Patel; Fiona D Barr; Charles R Wira
Journal:  Am J Reprod Immunol       Date:  2016-06-19       Impact factor: 3.886

9.  The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.

Authors:  Howard Y Li; Maria McSharry; Bonnie Bullock; Teresa T Nguyen; Jeff Kwak; Joanna M Poczobutt; Trisha R Sippel; Lynn E Heasley; Mary C Weiser-Evans; Eric T Clambey; Raphael A Nemenoff
Journal:  Cancer Immunol Res       Date:  2017-08-17       Impact factor: 11.151

Review 10.  Manipulating the PD-1 pathway to improve immunity.

Authors:  Alice O Kamphorst; Rafi Ahmed
Journal:  Curr Opin Immunol       Date:  2013-04-09       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.